Drug interactions with the androgen balance of adult men;Interactions médicamenteuses avec l'équilibre androgénique de l'homme adulte

Progres en Urologie

Volumn 14, Issue 5, 2004, Pages 679-683

  Sibert, L ^a   Kuhn, J M ^a   Rossi, D ^b   Tostain, J ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTIZIDE; AMINOGLUTETHIMIDE; ANDROGEN; ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; AZASTEROID; BENZAMIDE; BICALUTAMIDE; CHORIONIC GONADOTROPIN; CIMETIDINE; CLOMIFENE; CYPROTERONE ACETATE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUTAMIDE; FUROSEMIDE; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KETOCONAZOLE; MICONAZOLE; NILUTAMIDE; PHENOTHIAZINE DERIVATIVE; RECOMBINANT LUTEINIZING HORMONE; SPIRONOLACTONE; TAMOXIFEN; UNINDEXED DRUG;

ANDROGEN SYNTHESIS; DRUG ACTIVITY; DRUG EFFECT; HUMAN; REVIEW;

ADULT; ANDROGEN ANTAGONISTS; ANDROGENS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; TESTIS;

EID: 11244259406     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult males - 2002 update. Endocr Pract, 2002, 8, 440-456.
2. EIL C.: Ketoconazole binds to the human androgen receptor. Horm Metab Res, 1992, 24, 367-370.
3. EIL C., EDELSON S.K.: The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab, 1984, 59, 51-55.
4. FOREST M.: How should we perform the human chorionic gonadotrophin (hCG) stimulation test? Int J Androl, 1983, 6, 1.
5. KAMISCHKE A., KEMPER D.E., CASTEL M.A., LUTHKE M., ROLF C., BEHRE H.M., MAGNUSSEN H., NIESCHLAG E.: Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J, 1998, 11, 41-45.
6. KUHN J., SIBERT L.: Les pathologies du vieillissement masculin. Montrouge, F, John Libbey Eurotext, 2002, 165p.
7. KUHN J.M., LAUDAT M.H., WOLF L.M., LUTON J.P.: Hypertestosté ronémies masculines. Presse Med, 1987, 16, 675-679.
8. KUHN J.M., LUTON J.P.: Médicaments androgéniques et anti-androgéniques. Rev Prat, 1987, 37, 347-355.
9. LABRIE F.: Mechanism of action and pure antiandrogenic properties of flutamide. Cancer, 1993, 72, 3816-3827.
10. MACADAMS M.R., WHITE R.H., CHIPPS B.E.: Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med, 1986, 104, 648-651.
11. MULLIGAN T., IRANMANESH A., KERZNER R., DEMERS L.M., VELDHUIS J.D.: Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol, 1999, 141, 257-266.
12. RAUDRANT D., RABE T.: Progestogens with antiandrogenic properties. Drugs, 2003, 63, 463-492.
13. SANTEN R.J., PAULSEN C.A.: Hypogonadotrophic eunuchoidism. II. Gonadal responsiveness to exogenous gonadotropins. J Clin Endocrinol Metab, 1973, 36, 55-63.
14. SINGH S.M., GAUTHIER S., LABRIE F.: Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem, 2000, 7, 211-247.
15. SPRATT D.I., CHIN W.W., RIDGWAY E.C., CROWLEY W.F., JR.: Administration of low dose pulsatile gonadotropin-releasing hormone (GnRH) to GnRH-deficient men regulates free alpha-subunit secretion. J Clin Endocrinol Metab, 1986, 62, 102-108.